Physician

Kristyn Sayball, DO

According to 2025 Medicare claims, Kristyn Sayball, DO (NPI: 1962638973) practices pulmonary disease in the Richmond, VA market, with the plurality of this provider's patient population coming from Chesterfield, VA. This provider's primary affiliated billing organization is PULMONARY ASSOCIATES OF RICHMOND INC (NPI: 1144253444; TIN: 540965764) and primary practice location at 23225-5515.

Sayball's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 943 traditional Medicare patients, billed 43,533 HCPCS/CPT codes, and received $1,278,716 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 4,693 prescription claims across 775 beneficiaries totaling $1,409,285 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 1,551 claims. Open Payments data shows 26 records totaling $529. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $37,906 to $1,278,716. Similarly, Part D prescription costs have moved sharply higher in recent years, from $2,455 to $1,409,285. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $2,114 to $70,258.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	173	383	$37,906
2017	656	1,621	$137,454
2018	729	6,623	$270,586
2019	736	12,727	$443,981
2020	743	16,764	$611,403
2021	544	16,700	$654,997
2022	476	15,417	$544,863
2023	842	27,034	$874,535
2024	943	43,533	$1,278,716

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	11	$2,455
2016	22	38	$3,460
2017	76	290	$64,532
2018	114	552	$133,917
2019	152	835	$282,214
2020	225	1,338	$648,030
2021	277	1,941	$629,107
2022	342	2,308	$677,007
2023	532	3,008	$961,262
2024	775	4,693	$1,409,285

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	252	$18,094
2018	27	351	$29,540
2019	95	695	$35,599
2020	165	747	$29,269
2021	118	732	$20,077
2022	168	789	$26,505
2023	259	1,197	$52,716
2024	290	1,551	$81,096

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	143	143	$113
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	584	934	$91
94729	Test to examine how well the lungs exchange gases	155	158	$42
94726	Test to determine lung volumes using sensors	157	160	$40
96372	Injection of drug or substance under skin or into muscle	154	643	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	559	20,430	$432,476
Ofev	Nintedanib Esylate	14	420	$181,517
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	134	5,040	$105,022
Spiriva Respimat	Tiotropium Bromide	104	4,650	$80,342
Breo Ellipta	Fluticasone/Vilanterol	156	5,400	$68,706

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	58	468	$34,508
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	18	$13,739
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	N/R	12	$12,142
E1392	Portable oxygen concentrator, rental	Y	49	342	$12,038
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	36	102	$2,481

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	26	$529	GENZYME CORPORATION
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kristyn Sayball, DO?

Tedicare shows public-source Medicare data for Kristyn Sayball, DO (NPI 1962638973), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kristyn Sayball, DO have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Kristyn Sayball, DO?

Kristyn Sayball, DO is linked to PULMONARY ASSOCIATES OF RICHMOND INC (billing NPI 1144253444) in the available physician profile data.

Does Kristyn Sayball, DO have Open Payments data?

Kristyn Sayball, DO has 26 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.